tiprankstipranks
Inhibrx Biosciences, Inc. (INBX)
:INBX
US Market
Holding INBX?
Track your performance easily

Inhibrx Biosciences Inc (INBX) Stock Price & Analysis

16 Followers

INBX Stock Chart & Stats


Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

27.36%6.17%<0.01%58.32%
27.36% Insiders
<0.01% Other Institutional Investors
58.32% Public Companies and Individual Investors

INBX FAQ

What was Inhibrx Biosciences, Inc.’s price range in the past 12 months?
Inhibrx Biosciences, Inc. lowest stock price was $10.80 and its highest was $18.95 in the past 12 months.
    What is Inhibrx Biosciences, Inc.’s market cap?
    Inhibrx Biosciences, Inc.’s market cap is $196.00M.
      When is Inhibrx Biosciences, Inc.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Inhibrx Biosciences, Inc.’s earnings last quarter?
      Inhibrx Biosciences, Inc. released its earnings results on Aug 13, 2024. The company reported $125.48 earnings per share for the quarter, beating the consensus estimate of -$3.6 by $129.08.
        Is Inhibrx Biosciences, Inc. overvalued?
        According to Wall Street analysts Inhibrx Biosciences, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Inhibrx Biosciences, Inc. pay dividends?
          Inhibrx Biosciences, Inc. does not currently pay dividends.
          What is Inhibrx Biosciences, Inc.’s EPS estimate?
          Inhibrx Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Inhibrx Biosciences, Inc. have?
          Inhibrx Biosciences, Inc. has 14,475,904 shares outstanding.
            What happened to Inhibrx Biosciences, Inc.’s price movement after its last earnings report?
            Inhibrx Biosciences, Inc. reported an EPS of $125.48 in its last earnings report, beating expectations of -$3.6. Following the earnings report the stock price went down -3.489%.
              Which hedge fund is a major shareholder of Inhibrx Biosciences, Inc.?
              Currently, no hedge funds are holding shares in INBX
              ---

              Company Description

              Inhibrx Biosciences, Inc.

              Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
              ---
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis